Hollestelle, A, van der Baan, FH, Berchuck, A, Johnatty, SE, Aben, KK, Agnarsson, BA
, Aittomäki, K, Alducci, E, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Antoniou, AC, Apicella, C, Arndt, V, Arnold, N, Arun, BK, Arver, B, Ashworth, A, Baglietto, L, Balleine, R, Bandera, EV, Barrowdale, D, Bean, YT, Beckmann, L, Beckmann, MW, Benitez, J, Berger, A, Berger, R, Beuselinck, B, Bisogna, M, Bjorge, L
, Blomqvist, C, Bogdanova, NV, Bojesen, A, Bojesen, SE, Bolla, MK, Bonanni, B, Brand, JS, Brauch, H, Brenner, H, Brinton, L, Brooks-Wilson, A, Bruinsma, F, Brunet, J, Bruning, T
, Butzow, R, Leminen, A, Muranen, TA, Nevanlinna, H, Pelttari, LM, Ovarian Canc Assoc Consortium, Breast Canc Assoc Consortium, Consortium Modifiers BRCA1 & BRCA2, Australian Ovarian Canc Study Grp , Breast Cancer Family Register, EMBRACE, GEMO Study Collaborators, GENICA Network , HEBON, kConFab Investigators & SWE-BRCA 2016, '
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer',
Gynecologic Oncology, vol. 141, no. 2, pp. 386-401.
https://doi.org/10.1016/j.ygyno.2015.04.034